A pilot study: potential role of nutrient vitamin D in prostate cancer patients with rising PSA after definitive therapy

被引：0
|
作者：
Choo, R.
Woo, T.
Veith, R.
Jamieson, M.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[3] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [41] Tolerability of ongoing phase II study of concomitant radiation and docetaxel followed by docetaxel in prostate cancer patients with a persistent or rising PSA after radical prostatectomy
    Harris, A. M.
    Eng, T. Y.
    Karnad, A. B.
    Swanson, G. P.
    Jenkins, C.
    Greene, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Clinical value of [11C] choline PET/CT in patients with rising PSA after primary treatment of prostate cancer
    Rinnab, Ludwig
    Blumstein, Norbert M.
    Mottaghy, Felix M.
    Reske, Sven N.
    Hautmann, Richard E.
    Hohl, Kathrin
    Wiegel, Thomas
    Gschwend, Juergen E.
    Kuefer, Rainer
    JOURNAL OF UROLOGY, 2007, 177 (04): : 336 - 336
  • [43] Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
    Neal D. Shore
    Judd W. Moul
    Kenneth J. Pienta
    Johannes Czernin
    Martin T. King
    Stephen J. Freedland
    Prostate Cancer and Prostatic Diseases, 2024, 27 : 192 - 201
  • [44] Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer
    Hellerstedt, B
    UROLOGY, 2003, 62 (6B) : 79 - 86
  • [45] Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
    Shore, Neal D.
    Moul, Judd W.
    Pienta, Kenneth J.
    Czernin, Johannes
    King, Martin T.
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (02) : 192 - 201
  • [46] PROSTATIC SPECIFIC ANTIGEN (PSA) AND BONE SCANNING IN FOLLOW-UP OF PROSTATE-CANCER PATIENTS S/P DEFINITIVE THERAPY
    GILVYDIS, RP
    FREITAS, JE
    FERRY, JD
    BLAKE, DC
    GONZALEZ, JA
    JOURNAL OF NUCLEAR MEDICINE, 1989, 30 (04) : AB9 - AB9
  • [47] Rapid time to prostate-specific antigen nadir after androgen deprivation therapy is associated with vitamin d deficiency in prostate cancer patients
    Amadi, C.
    Amadi, B. C.
    Odum, E. P.
    Okafor, J. C.
    CLINICA CHIMICA ACTA, 2024, 558 : 52 - 52
  • [48] Reduction of PSA values after levofloxacin therapy in patients with PSA greater than 4 ng/ml: Implications for prostate cancer detection
    Bozdogan, G.
    Erol, B.
    Akduman, B.
    Tokgoz, H.
    Donmez, I.
    Mungan, G.
    Mungan, N. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (08) : 577 - 577
  • [49] MRI EVALUATION OF PROSTATE VOLUME SHRINKAGE AFTER NEOADJUVANT HORMONE THERAPY IN PROSTATE CANCER PATIENTS TREATED WITH DEFINITIVE HYPOFRACTIONATED RADIOTHERAPY
    Liardo, Rocco Luca Emanuele
    Bevilacqua, Roberta
    Tocco, Alessandra
    Privitera, Giuseppe
    Spatola, Corrado
    ANTICANCER RESEARCH, 2015, 35 (06) : 3644 - 3644
  • [50] Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer
    Rodrigues, Neesha A.
    Chen, Ming-Hui
    Catalona, William J.
    Roehl, Kimberly A.
    Richie, Jerome R.
    D'Amico, Anthony V.
    CANCER, 2006, 107 (03) : 514 - 520
12345